- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01298388
Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998
Assessment of the Long Term Outcome of Childhood ALL Patients Enrolled in EORTC Children's Leukemia Group Trials Between 1971 and 1998
RATIONALE: Studying medical records and collecting questionnaires from patients who were enrolled as children in clinical trials for acute lymphoblastic leukemia may help doctors learn about long-term effects of treatment and plan the best treatment.
PURPOSE: This clinical trial is studying the long-term outcomes of patients with acute lymphoblastic leukemia who were enrolled as children on clinical trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 between 1971 and 1998.
Study Overview
Status
Detailed Description
OBJECTIVES:
- To assess the long-term outcomes (i.e., long-term survival, long-term disease status, occurrence of late adverse effects, occurrence of second cancers, and socioeconomic status of survivors) of patients with acute lymphoblastic leukemia previously enrolled as children on clinical trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 between the years of 1971 and 1998.
OUTLINE: Long-term outcome data are collected from the databases about clinical trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881. Other data collected include the patient's vital status actualization (e.g., alive, dead or lost to follow up, date last known to be alive or date of death), medical records data, and the collection of data from patients confirmed to be alive (e.g., data related to marital status, education, work, insurance, puberty, fertility, and offspring) by questionnaire.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Patients with acute lymphoblastic leukemia (ALL) previously enrolled as children (less than18 years of age at diagnosis) on any of the following clinical trials between 1971 and 1998:
- EORTC-58741
- EORTC-58831
- EORTC-58832
- EORTC-58881
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Study Plan
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Disease status
|
|
Second cancers
|
|
Long-term survival
|
|
Late adverse effects
|
|
Socioeconomic status of survivors
|
Collaborators and Investigators
Investigators
- Study Chair: Caroline Piette, Centre Hospitalier Régional de la Citadelle
- Yves Benoit, MD, Universitair Ziekenhuis Gent
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- cancer survivor
- childhood acute lymphoblastic leukemia in remission
- untreated childhood acute lymphoblastic leukemia
- long-term effects secondary to cancer therapy in children
- recurrent childhood acute lymphoblastic leukemia
- non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
- non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
- non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
- T-cell childhood acute lymphoblastic leukemia
- non-T, non-B childhood acute lymphoblastic leukemia
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000695273
- EORTC-58LAE
- EU-21106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.